Preventing Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in High-Risk Patients: Protocol of a Randomized Placebo-Controlled Trial of Prednisone (PredART Trial)

Cari Stek   ^{1, 2, 3} , MD ;   Charlotte Schutz   ^{1, 3} , MBChB, DipHIVMan(SA), MPH ;   Lisette Blumenthal   ^{1, 3} , MBChB, DipHIVMan(SA) ;   Friedrich Thienemann   ^{1, 3} , MD ;   Jozefien Buyze   ² , PhD ;   Christiana Nöstlinger   ⁴ , PhD ;   Raffaella Ravinetto   ² , PharmD, PhD ;   Edwin Wouters   ⁵ , PhD ;   Robert Colebunders   ² , MD, PhD ;   Gary Maartens   ³ , MMed ;   Robert J Wilkinson   ^{1, 3, 6, 7} , MA, BMBCh, DTM&H, PhD ;   Lutgarde Lynen   ² , MD, PhD ;   Graeme Meintjes   ^{1, 3} , MBChB, FCP(SA), FRCP(UK), DipHIVMan(SA), MPH, PhD

¹ Institute of Infectious Disease and Molecular Medicine, Clinical Infectious Diseases Research Initiative, University of Cape Town, Cape Town, South Africa

² Institute of Tropical Medicine, Department of Clinical Sciences, Antwerp, Belgium

³ Department of Medicine, University of Cape Town, Cape Town, South Africa

⁴ Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium

⁵ Department of Sociology, Centre for Longitudinal and Life Course Studies, University of Antwerp, Antwerp, Belgium

⁶ Department of Medicine, Imperial College London, London, United Kingdom

⁷ The Francis Crick Institute, Mill Hill Laboratory, London, United Kingdom